Browse All

Current Filters

CLEAR FILTER x

TITLE

Prognostic Value of On-treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People with Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials

Author:Leist, Thomas   Hauser, Stephen   Derfuss, Tobias   Wiendl, Heinz   Arnold, Douglas   Montalban, Xavier   Bhatt, Alit   Wei, Wenjia   Boer, Ibolya   Alvarez, Enrique   Ziemssen, Tjalf   

Session Name:S42: Multiple Sclerosis: Biomarkers/Neuroimaging  

Topic:Multiple Sclerosis  

Program Number:S42.003  

Author Institution:Thomas Jefferson University, Philadelphia, PA, USA, Philadelphia, PA  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA  Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland, Basel, Switzerland  Institute of Translational Neurology, University of Münster, Münster, Germany, Muenster, Germany  Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada, Montreal, QC, Canada  Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d’Hebron University Hospital, Barcelona, Spain, Barcelona, Spain  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Basel, Switzerland  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Novartis Pharma AG, Basel, Switzerland , Basel, Switzerland  Rocky Mountain MS Center, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany  

Long-term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis

Author:Bar-Or, Amit   Wiendl, Heinz   De Seze, Jerome   Correale, Jorge   Cross, Anne   Derfuss, Tobias   Selmaj, Krzysztof   Winthrop, Kevin   Giacomini, Paul   Sacca, Francesco   Hu, Xixi   Sullivan, Roseanne   Jehl, Valentine   Boer, Ibolya   Bhatt, Alit   Hauser, Stephen   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.007  

Author Institution:Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA  University of Muenster, Muenster, Germany  University Hospital of Strasbourg, Strasbourg, France  Institute for Neurological Research Dr. Raul Carrea, Buenos Aires, Argentina  Washington University School of Medicine, Clayton, MO  Neurology Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine and Biomedicine, University Hospital and University of Basel, Basel, Switzerland  Center for Neurology, Lodz, Lodz, Poland  Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR  Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada  NSRO Department, University “Federico II” of Naples, Naples, Italy  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma AG, Basel, Switzerland  Novartis Healthcare Pvt. Ltd., Hyderabad, India  UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA